Liver cirrhosis patients needed for blood thinner safety study

NCT ID NCT04874428

Recruiting now Knowledge-focused Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

First seen Mar 01, 2026 · Last updated May 01, 2026 · Updated 8 times

Summary

This study looks at how two common blood thinners, rivaroxaban and apixaban, are processed by the body in people with mild to moderate liver cirrhosis (Child-Pugh class A and B). Participants take a single low dose of one of the drugs, and blood samples are collected over 12 hours to measure drug levels and clotting activity. The goal is to better understand dosing and safety in this group. A follow-up call 5 days later checks for any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Department of Visceral Surgery and Medicine, University Hospital Inselspital, Berne
RECRUITING

Bern, 3010, Switzerland

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LIVER CIRRHOSIS